A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.

Schulze, Kai; Staib, Caroline; Schätzl, Hermann M; Ebensen, Thomas; Erfle, Volker; Guzman, Carlos A

dc.contributor.author	Schulze, Kai
dc.contributor.author	Staib, Caroline
dc.contributor.author	Schätzl, Hermann M
dc.contributor.author	Ebensen, Thomas
dc.contributor.author	Erfle, Volker
dc.contributor.author	Guzman, Carlos A
dc.date.accessioned	2009-12-04T12:59:14Z	en
dc.date.available	2009-12-04T12:59:14Z	en
dc.date.issued	2008-12-02	en
dc.identifier.citation	A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus. 2008, 26 (51):6678-84 Vaccine	en
dc.identifier.issn	0264-410X	en
dc.identifier.pmid	18805454	en
dc.identifier.doi	10.1016/j.vaccine.2008.09.006	en
dc.identifier.uri	http://hdl.handle.net/10033/87413	en
dc.description.abstract	Severe acute respiratory syndrome (SARS) is a serious infectious disease caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based on the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA-NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in priming with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA-NC by intramuscular route.
dc.language.iso	en	en
dc.subject.mesh	Adjuvants, Immunologic	en
dc.subject.mesh	Administration, Intranasal	en
dc.subject.mesh	Animals	en
dc.subject.mesh	Antibodies, Viral	en
dc.subject.mesh	Immunity, Cellular	en
dc.subject.mesh	Immunization, Secondary	en
dc.subject.mesh	Immunoglobulin A	en
dc.subject.mesh	Injections, Intramuscular	en
dc.subject.mesh	Lipopeptides	en
dc.subject.mesh	Mice	en
dc.subject.mesh	Mice, Inbred BALB C	en
dc.subject.mesh	Nucleocapsid Proteins	en
dc.subject.mesh	SARS Virus	en
dc.subject.mesh	Severe Acute Respiratory Syndrome	en
dc.subject.mesh	Vaccinia virus	en
dc.subject.mesh	Viral Vaccines	en
dc.title	A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.	en
dc.type	Article	en
dc.contributor.department	Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7, D-38124 Braunschweig, Germany.	en
dc.identifier.journal	Vaccine	en
refterms.dateFOA	2018-06-13T16:59:55Z
html.description.abstract	Severe acute respiratory syndrome (SARS) is a serious infectious disease caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based on the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA-NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in priming with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA-NC by intramuscular route.